Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

Early clinical course of biopsy-proven IgA vasculitis nephritis

BMC Pediatrics volume 22, Article number: 570 (2022) Cite this article

Abstract

Background

IgA vasculitis (IgAV) is the most common form of systemic vasculitis in childhood and frequently involves the kidney. A minority of patients with IgA vasculitis nephritis (IgAVN), especially those presenting with heavy proteinuria and/or kidney failure at onset, are at risk of chronic end-stage kidney disease. For deciding upon treatment intensity, knowledge of the short-term clinical course of IgAVN is needed to improve treatment algorithms.

Methods

For this retrospective multicenter study, the medical records of 66 children with biopsy-proven IgAVN were reviewed. Age, gender, medical history and therapeutic interventions were recorded. Laboratory data included serum creatinine, albumin, urinary protein excretion (UPE) and glomerular filtration rate (eGFR). Threshold values were determined for each parameter, full remission was defined as no proteinuria and eGFR > 90 ml/min/1.73m2.

Results

Median age at onset of IgAVN was 8.9 years. 14.1% of the children presented with nephrotic syndrome, 50% had an eGFR below 90 ml/min/1.73 m2 and 51.5% showed cellular crescents in renal histology. The treatment regimens varied notably. Forty-four patients were treated with immunosuppression; 17 patients with crescents or nephrotic syndrome were treated with corticosteroid (CS) pulse therapy. After 6 months, UPE had decreased from 3.7 to 0.3 g/g creatinine and the proportion of patients with a decreased eGFR had fallen from 50.0% to 35.5%. Thirteen children (26.5%) achieved full remission within 6 months.

Conclusions

In most patients with IgAVN proteinuria decreases slowly and kidney function improves, but full remission is reached only in a minority after 6 months. Persistent heavy proteinuria in the first two months rarely developed into long-term proteinuria. Therefore, decisions for more intense treatment should take into account the course of UPE over time.

For a comparison of treatment effects, patient numbers were too small. Prospective, randomized controlled trials are necessary to clarify risk factors and the effect of immunosuppressive therapies.

Peer Review reports

Background

IgA vasculitis (IgAV; formerly known as Henoch-Schönlein purpura) is the most common vasculitis in childhood with a peak incidence at 4–7 years [1]. Renal involvement occurs in 30–60% of the patients [2]. The majority of these patients presents with mild symptoms and recovers without residual damage. A small percentage develops nephrotic and/or nephritic syndrome sometimes leading to permanent organ damage and the need for kidney replacement therapy [3,4,5,6,7]. Known risk factors for permanent renal damage are aggressive lesions in the initial kidney biopsy, the presence of nephrotic and/or nephritic syndrome, hypertension and a relapsing course of the disease [3, 4, 6, 8, 9]. However, it is still not clear how intensive treatment should be. A 5-year kidney survival of 83% and an even lower 10-year kidney overall survival of 73% [4], as well as a high risk of dialysis in selected patients [5] might justify immunosuppressive therapy. On the other hand, patients with severe initial kidney involvement can achieve complete remission without any intervention [10]. Due to the lack of evidence-based treatment strategies and the unpredictable individual prognosis, various therapeutic regimens exist, ranging from immunosuppressive monotherapy to diverse combinations of prednisolone, mycophenolate mofetil (MMF), cyclosporine A (CSA), cyclophosphamide (CYC), azathioprine (AZA), rituximab and plasmapheresis. Early treatment initiation appears to be decisive for therapeutic success [11,12,13,14,15]. In order to describe the short-term renal course, we evaluated 66 patients with biopsy-proven IgA vasculitis nephritis (IgAVN; formerly known as Henoch-Schönlein purpura nephritis) and highly heterogeneous treatment strategies. Clinical symptoms, proteinuria and glomerular filtration rate were recorded at diagnosis and during the following 6-months to assess the clinical course, response and remission rates. We hope knowledge of the typical renal outcome will lead to more evidence-based treatment algorithms.

Methods

Study design

This descriptive retrospective cohort study is based on the German Henoch-Schönlein purpura nephritis register, supported by the German Society of Pediatric Nephrology (GPN). All patients were enrolled from seven pediatric nephrology departments (Munich, Cologne, Hamburg, Berlin, Erlangen, Muenster and Freiburg). Inclusion criteria were age 0–18 years, purpura before onset of nephritis and biopsy-proven IgAVN including mesangial IgA-deposition on kidney biopsy. Patients with comorbidities, chronic illness or prior kidney disease were excluded, resulting in a total cohort of 66 patients. Information about the initial onset of nephritis as well as all follow-up visits during the first 6 months (month #1 (M1) – month #6 (M6)) was collected on site by review of the patient files. The study complied with the Declaration of Helsinki and was approved by the ethics committee of the Albert Ludwig’s University of Freiburg, Germany.

Definitions, clinical and laboratory parameters

Age, gender, five main clinical features (purpura, edema, arthritis, abdominal pain and hypertension) and hematuria (macroscopic or microscopic) were documented. In terms of laboratory results we noted the highest level of proteinuria [urinary protein/creatinine ratio in g/g or g/m2/day in 24 h-urine sampling] and serum creatinine [mg/dl] and the lowest level of serum albumin [mg/dl] and glomerular filtration rate [ml/min/1.73m2]. The estimated glomerular filtration rate (eGFR) was calculated with the modified Schwartz formula [16]. Nephrotic-range proteinuria was defined as > 2.0 g/g creatinine in spot urine sampling or > 1.0 g/m2/day in 24 h-urine sampling. Non-nephrotic range proteinuria was defined as urinary loss of protein between 0.2 – 2.0 g/g creatinine or 0.15 – 1.0 g/m2/day respectively. The cut-off for impaired eGFR was specified as < 90 ml/min/1.73m2. Serum albumin levels were considered normal between 35–55 mg/dl. Nephrotic syndrome was defined as nephrotic-range proteinuria with either decreased serum albumin < 25 mg/dl or edema. Nephritic syndrome was diagnosed when hematuria and a decrease of eGFR were present. Hypertension was assessed by the local attending physician. Complete remission was defined as eGFR > 90 ml/min/1.73m2 and no proteinuria (< 0.2 g/g creatinine or < 0.15 g/m2/day).

Histology

Results of the kidney biopsy were obtained from the local pathologists’ reports. We evaluated proportion and type of crescents as well as chronic lesions. Cellular and fibrocellular crescents were classified as acute lesions. On the contrary, fibrous crescents, > 5% tubular atrophy, > 5% tubulointerstitial fibrosis and glomerulosclerosis were categorized as chronic lesions.

Statistics

Variables were tested for normal distribution using the Shapiro–Wilk test. Normally distributed variables were compared using Student’s t-test, whereas the Wilcoxon signed-rank test was used when variables were not normally distributed. Results are given as median and interquartile range (IQR). The chi-square test was applied for dichotomous features. P-values < 0.05 were considered significant.

Results

Patient characteristics and parameters at onset of diagnosis

Sixty-six patients with biopsy-proven IgAVN were included in the study. Diagnosis was confirmed between March 1999 and March 2012. 33 (50%) were female and 33 (50%) male. Median age at diagnosis was 8.9 (IQR 6.1–11.4) years. Patient characteristics at onset of nephritis are given in Table 1.

Table 1 Patient characteristics of 66 patients with biopsy-proven IgA vasculitis nephritis (IgAVN) at onset of nephritis. The number of patients varies because of missing values
Full size table

Treatment

The treatment regimens of our 66 patients varied notably (Fig. 1). Throughout the 6 months of the follow-up period, 69.7% (n = 46/66) of the patients were treated with immunosuppression. Among these, CS, MMF, CYC and CSA were used in various combinations. 90.9% (n = 60/66) received angiotensin converting enzyme (ACE-) inhibitors, 9.1% (n = 6/66) had angiotensin II receptor subtype 1 (AT1-) antagonists additionally. 17 patients with crescents or nephrotic syndrome were treated with CS pulse therapy (3 × 300 mg/m2 every 48 h), followed by a CS maintenance therapy (60 mg/m2 for 3 weeks, 40 mg/m2 for another 4 weeks) according to the recommendations of the GPN. 11 patients were not treated with immunosuppressive therapy despite the presence of crescents in their kidney biopsy.

Fig. 1
figure 1

Proportional distribution of different immunosuppressive therapy regimens. 1) corticosteroid pulse therapy + maintenance therapy with oral corticosteroids. 2) oral corticosteroids only. 3) corticosteroid pulse therapy + maintenance therapy with oral corticosteroids + other immunosuppressants. 4) oral corticosteroids + other immunosuppressants. 5) other immunosuppressants only. 6) no immunosuppressants

Full size image

Histology

According to the inclusion criteria, all patients (n = 66/66) showed mesangial IgA-depositions on kidney biopsy. A median of 19 (IQR 13–34) glomeruli per biopsy sample were analysed. 72.7% (n = 48/66) of the patients showed crescents in their biopsy, a median of 18.8% (IQR 11.3 – 24.1) glomeruli were affected by these findings. The proportion of crescents is illustrated in Fig. 2. None of the patients presented with crescents in more than 75% of the glomeruli of the kidney biopsy. Cellular crescents were described in 70.8% (n = 34/48) of these cases, fibrocellular crescents in 10.4% (5/48) and fibrous crescents in 12.5% (n = 6/48). However, in 20.8% (n = 10/48) no further specifications were made regarding the type of crescents. Chronic lesions were present in 48.5% (n = 32/66) of the patients comprising fibrous crescents, > 5% tubular atrophy, > 5% tubulointerstitial fibrosis or glomerulosclerosis.

Fig. 2
figure 2

Proportional distribution of glomeruli with crescents (cellular, fibrous, fibrocellular)

Full size image

Six-months clinical course

A median of 4.6 (range: 1—10) outpatient visits were recorded during the first six months of follow-up. Hospital admission was necessary in 20 patients (30.3%) during that time. During the first 3 and 6 months all five clinical symptoms (purpura, edema, hypertension, arthritis, abdominal pain) decreased significantly in comparison to the initial presentation (p < 0.01 in all 3- and 6-months values vs. onset). Table 2 illustrates the improvement of renal impairment and the decrease of proteinuria as well as the decreasing proportion of patients with nephrotic-range proteinuria and the increase of patients achieving remission. Median proteinuria decreased significantly within 3 and 6 months, as did the proportion of patients with nephrotic-range proteinuria. Within the group of patients with heavy proteinuria at onset of disease, proteinuria dropped in greater extent compared to patients with initial non-nephrotic range proteinuria (from 5 to 0.25 g/g Creatinine vs. 1 g/g to 0.4 g/g Creatinine after 6 months). Figure 3 visualizes the major decrease of median proteinuria within the first 2 months. After 4 months, two patients (n = 2/52) and after 6 months more than one quarter of the patients (n = 13/49) had achieved complete remission. When comparing groups with different therapeutic regimens, no significant impact on the course of the nephritis was found. Treated and untreated patients with similar histological and clinical presentation showed similar improvement of clinical symptoms and proteinuria (see additional file 1), but the patient number was too small for a meaningful data subanalysis.

Table 2 Changes of eGFR and proteinuria of the total cohort during the first 6 months of follow-up. P values are shown for the difference between the values at month 3 (M3) and month 6 (M6) versus the values at onset
Full size table
Fig. 3
figure 3

Six-month follow-up of proteinuria in 66 patients with biopsy-proven IgAVN. Median proteinuria dashed thick red line (-—-). Threshold heavy proteinuria thick yellow line (ꟷ·ꟷ·)

Full size image

Discussion

In our cohort all clinical symptoms (purpura, edema, hypertension, arthritis, abdominal pain) as well as the proportion of patients with macroscopic hematuria and nephrotic syndrome decreased significantly within 3 months. Proteinuria was reduced significantly as well within this time frame. Kidney function increased, albeit without achieving the level of significance within 6 months. After a period of 6 months 26.5% of the children were in complete remission. Prior studies rarely described the short-term course of IgAVN in detail and most referred to specific treatment regimens, so that it is difficult to base clinical treatment decisions on the published literature. Treatment in the patient cohort was highly variable which complicates comparison between different regimens. Between the small subgroups no significant impact of the treatment decisions could be shown. The majority of the reports published to date focused on corticosteroids intravenously or orally, often combined with other immunosuppressive drugs. In adults, a beneficial effect of corticosteroids has been postulated in patients with IgAN [17, 18], but they did not improve the outcome in a large randomized trial [19, 20]. In children with IgAVN there are no large randomized studies available. As illustrated in detail in Table 3 and discussed below, several previous studies described the short-term follow-up at specific time points using specified therapeutic regimens, whereas our study depicts the individual time course of proteinuria and kidney function after the diagnosis of IgAVN regardless of the therapy.

Table 3 Published literature referring to short-term clinical course in children with IgAVN
Full size table

In contrast to the recently established European SHARE guideline [33] the recommendation of the German Society of Pediatric nephrology advocates an early biopsy [34]. Therefore, the patients in this cohort were biopsied relatively early and even in these early biopsies chronic changes were found in a significant percentage of patients. It appears that irreversible damage in IgAVN occurs either rapidly or the disease had been preexisting, so that early biopsies might be justified to estimate the individual patient prognosis.

The most profound improvement of renal impairment in our cohort was seen within one to two months of follow up which is consistent with a cohort published by Kawasaki et al., treated with a cyclophosphamide containing regimen [25]. Deng et al. evaluated treatment effects after an interval of four weeks [21]. Different therapeutic regimens were used in this study, ranging from non-steroid strategies to hydrocortisone sodium succinate, methylprednisolone pulse therapy and methylprednisolone in combination with tripterygium glycoside. While 60.8% of their patients presented decreasing proteinuria or no hematuria within this interval, 39.2% were stratified as non-responders and therefore received intensified treatment [21]. Our cohort clearly shows that patients continue to improve after the first four weeks. In another study by Ronkainen et al., seven patients with nephrotic-range proteinuria received CSA and were observed monthly for the first six months. All patients showed a certain response within a mean time of 1.4 months [28].

At 3 months, Niaudet et al. analysed children with biopsy-proven IgAVN treated with corticosteroids in an uncontrolled study. Similar to our cohort, their 38 patients showed a significant decrease in proteinuria within that timeframe [14]. Three cohorts receiving cyclophosphamide demonstrated similar results [22,23,24]. Cyclophosphamide in combination with corticosteroids was the therapy of choice in two of these cohorts [23, 24] whereas Wakaki et al. evaluated a heterogenous group of patients stratified by the International Study of Kidney Disease in Children (ISKDC) classification. Grade I-III were not treated with immunosuppressants, grade IV-V treated with corticosteroids with or without CYC, AZA and/or methylprednisolone pulse therapy [22]. Resembling our data, a significant reduction of proteinuria has been noticed [24]. Evaluation of the duration of proteinuria showed a reduction of proteinuria to non-nephrotic levels in 45.2% within 3 months [22]. In our cohort, the proportion of patients with nephrotic-range proteinuria decreased significantly from 80.3% to 11.5% within 3 months. Two groups of patients treated with CSA have been analysed after a period of 3 months [26, 27]. Jauhola et al. analysed 24 patients with at least ISKDC grade III and randomized them into a group treated with CSA and a group treated with methylprednisolone. Remission of nephrotic-range proteinuria has been achieved in all of CSA patients, whereas the remission rate of the control group was inferior and slower [27]. The second cohort received CSA when nephrotic-range proteinuria evolved during oral corticosteroid treatment. A response (defined as trace to negative proteinuria) was noted within 3.5 months in all patients. A small cohort treated with MMF after being found steroid-resistant demonstrated a mean response interval of 2.5 months with decreasing proteinuria to a minimum of 50% compared to pretreatment parameters [29].

At 4- and 5-months follow-up, Ninchoji et al. published 50 patients with moderate or severe IgAVN without immunosuppressive treatment and with prednisone and azathioprine or mizoribine respectively. Resolution of proteinuria was achieved in 50% of the patients by 4.3 months in those with moderate IgAVN and by 5.3 months in those with severe IgAVN [31]. Remission of proteinuria was obtained in a group of 18 patients treated according to their ISKDC grade with oral prednisolone with and without CYC with and without AZA by 4–6 months; the authors therefore discuss an escalating treatment algorithm according to severity [32].

A half-year follow-up was published in two heterogeneous patient cohorts [25, 30]. Kawasaki et al. evaluated mean UPE of 37 patients treated with either urokinase pulse therapy or urokinase pulse therapy plus cyclophosphamide, whereas Ren et al. looked at 53 patients who received MMF or prednisone. Proteinuria was decreased significantly in all groups at 6 months follow-up [25].

The short-term renal course of IgAVN over the first 6 months after kidney biopsy appears benign with regression of proteinuria and improvement of renal impairment in the overwhelming number of patients, but in our cohort complete remission was not observed before 3 months and is reached after 6 months in a minority of the patients. The data we present shows the typical initial course of IgAVN with current treatment after kidney biopsy. Decisions for or against aggressive immunosuppressive therapy should be based on this typical disease course and lacking improvement after 4 weeks not necessarily requires additional, more aggressive treatment.

Conclusion

In conclusion, we see improvement of kidney function and decreasing proteinuria in all patients in within the first months, but complete remission requires more time in most patients. Persistent heavy proteinuria in the first two months rarely developed into long-term proteinuria. Therefore, decisions for more intense treatment should take into account the course of UPE over time. Due to the retrospective design of the study, the effect of different immunosuppressive therapy regimens cannot be compared, but treated and untreated patients showed a similar time course of proteinuria.

For clarifying the effect of immunosuppressive therapy in IgAVN, prospective, randomized controlled multicenter trials are necessary.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

IgAV:

IgA vasculitis

IgAVN:

IgA vasculitis nephritis

UPE:

Urinary protein excretion

eGFR:

Estimated glomerular filtration rate

CS:

Corticosteroids

MMF:

Mycophenolate mofetil

CSA:

Cyclosporine A

CYC:

Cyclophosphamide

AZA:

Azathioprine

ACE:

Angiotensin converting enzyme

AT1:

Angiotensin II receptor subtype 1

IQR:

Interquartile range

ISKDC:

International Study of Kidney Disease in Children

References

  1. Gardner-Medwin JMM, Dolezalova P, Cummins C, et al. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360:1197–202. https://doi.org/10.1016/S0140-6736(02)11279-7.

    Article  PubMed  Google Scholar 

  2. Pohl M. Henoch-Schönlein purpura nephritis. Pediatr Nephrol. 2015;30:245–52. https://doi.org/10.1007/s00467-014-2815-6.

    Article  PubMed  Google Scholar 

  3. Goldstein AR, White RH, Akuse R, et al. Long-term follow-up of childhood Henoch-Schönlein nephritis. Lancet. 1992;339:280–2. https://doi.org/10.1016/0140-6736(92)91341-5.

    Article  PubMed  CAS  Google Scholar 

  4. Schärer K, Krmar R, Querfeld U, et al. Clinical outcome of Schönlein-Henoch purpura nephritis in children. Pediatr Nephrol. 1999;13:816–23. https://doi.org/10.1007/s004670050707.

    Article  PubMed  Google Scholar 

  5. Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study. Lancet. 2002;360:666–70. https://doi.org/10.1016/S0140-6736(02)09835-5.

    Article  PubMed  Google Scholar 

  6. Calviño MC, Llorca J, García-Porrúa C, et al. Henoch-Schönlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine (Baltimore). 2001;80:279–90. https://doi.org/10.1097/00005792-200109000-00001.

    Article  Google Scholar 

  7. Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore). 1999;78:395–409. https://doi.org/10.1097/00005792-199911000-00005.

    Article  CAS  Google Scholar 

  8. Foster BJ, Bernard C, Drummond KN, et al. Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J Pediatr. 2000;136:370–5. https://doi.org/10.1067/mpd.2000.103448.

    Article  PubMed  CAS  Google Scholar 

  9. Edström Halling S, Söderberg MP, Berg UB. Predictors of outcome in Henoch-Schönlein nephritis. Pediatr Nephrol. 2010;25:1101–8. https://doi.org/10.1007/s00467-010-1444-y.

    Article  PubMed  Google Scholar 

  10. Meadow SR, Glasgow EF, White RH, et al. Schönlein-Henoch nephritis. Perspect Nephrol Hypertens. 1973;1(Pt 2):1089–104.

    PubMed  Google Scholar 

  11. Andersen RF, Rubak S, Jespersen B, et al. Early high-dose immunosuppression in Henoch-Schönlein nephrotic syndrome may improve outcome. Scand J Urol Nephrol. 2009;43:409–15. https://doi.org/10.3109/00365590903164480.

    Article  PubMed  CAS  Google Scholar 

  12. Hattori M, Ito K, Konomoto T, et al. Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schönlein purpura nephritis in children. Am J Kidney Dis. 1999;33:427–33. https://doi.org/10.1016/s0272-6386(99)70178-2.

    Article  PubMed  CAS  Google Scholar 

  13. Kawasaki Y, Suzuki J, Nozawa R, et al. Efficacy of methylprednisolone and urokinase pulse therapy for severe Henoch-Schönlein nephritis. Pediatrics. 2003;111:785–9. https://doi.org/10.1542/peds.111.4.785.

    Article  PubMed  Google Scholar 

  14. Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. Pediatr Nephrol. 1998;12:238–43. https://doi.org/10.1007/s004670050446.

    Article  PubMed  CAS  Google Scholar 

  15. Hennies I, Gimpel C, Gellermann J, et al. Presentation of pediatric Henoch-Schönlein purpura nephritis changes with age and renal histology depends on biopsy timing. Pediatr Nephrol. 2018;33:277–86. https://doi.org/10.1007/s00467-017-3794-1.

    Article  PubMed  Google Scholar 

  16. Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–37. https://doi.org/10.1681/ASN.2008030287.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157–63. https://doi.org/10.1097/01.asn.0000103869.08096.4f.

    Article  PubMed  CAS  Google Scholar 

  18. Cheng J, Zhang X, Zhang W, et al. Efficacy and safety of glucocorticoids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. Am J Nephrol. 2009;30:315–22. https://doi.org/10.1159/000226129.

    Article  PubMed  CAS  Google Scholar 

  19. Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015;373:2225–36. https://doi.org/10.1056/NEJMoa1415463.

    Article  PubMed  CAS  Google Scholar 

  20. Rauen T, Wied S, Fitzner C, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;98:1044–52. https://doi.org/10.1016/j.kint.2020.04.046.

    Article  PubMed  CAS  Google Scholar 

  21. Deng F, Lu L, Zhang Q, et al. Improved outcome of Henoch-Schonlein purpura nephritis by early intensive treatment. Indian J Pediatr. 2012;79:207–12. https://doi.org/10.1007/s12098-011-0519-5.

    Article  PubMed  Google Scholar 

  22. Wakaki H, Ishikura K, Hataya H, et al. Henoch-Schönlein purpura nephritis with nephrotic state in children: predictors of poor outcomes. Pediatr Nephrol. 2011;26:921–5. https://doi.org/10.1007/s00467-011-1827-8.

    Article  PubMed  Google Scholar 

  23. Iijima K, Ito-Kariya S, Nakamura H, et al. Multiple combined therapy for severe Henoch-Schönlein nephritis in children. Pediatr Nephrol. 1998;12:244–8. https://doi.org/10.1007/s004670050447.

    Article  PubMed  CAS  Google Scholar 

  24. Flynn JT, Smoyer WE, Bunchman TE, et al. Treatment of Henoch-Schönlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol. 2001;21:128–33. https://doi.org/10.1159/000046235.

    Article  PubMed  CAS  Google Scholar 

  25. Kawasaki Y, Suzuki J, Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study. Nephrol Dial Transplant. 2004;19:858–64. https://doi.org/10.1093/ndt/gfg617.

    Article  PubMed  CAS  Google Scholar 

  26. Park JM, Won SC, Shin JI, et al. Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol. 2011;26:411–7. https://doi.org/10.1007/s00467-010-1723-7.

    Article  PubMed  Google Scholar 

  27. Jauhola O, Ronkainen J, Autio-Harmainen H, et al. Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial. Pediatr Nephrol. 2011;26:2159–66. https://doi.org/10.1007/s00467-011-1919-5.

    Article  PubMed  Google Scholar 

  28. Ronkainen J, Autio-Harmainen H, Nuutinen M. Cyclosporin A for the treatment of severe Henoch-Schönlein glomerulonephritis. Pediatr Nephrol. 2003;18:1138–42. https://doi.org/10.1007/s00467-003-1245-7.

    Article  PubMed  Google Scholar 

  29. Du Y, Hou L, Zhao C, et al. Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil. Pediatr Nephrol. 2012;27:765–71. https://doi.org/10.1007/s00467-011-2057-9.

    Article  PubMed  Google Scholar 

  30. Ren P, Han F, Chen L, et al. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis. Am J Nephrol. 2012;36:271–7. https://doi.org/10.1159/000341914.

    Article  PubMed  CAS  Google Scholar 

  31. Ninchoji T, Kaito H, Nozu K, et al. Treatment strategies for Henoch-Schönlein purpura nephritis by histological and clinical severity. Pediatr Nephrol. 2011;26:563–9. https://doi.org/10.1007/s00467-010-1741-5.

    Article  PubMed  Google Scholar 

  32. Altugan FS, Ozen S, Aktay-Ayaz N, et al. Treatment of severe Henoch-Schönlein nephritis: justifying more immunosuppression. Turk J Pediatr. 2009;51:551–5.

    PubMed  Google Scholar 

  33. Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford). 2019;58:1607–16. https://doi.org/10.1093/rheumatology/kez041.

    Article  CAS  Google Scholar 

  34. Pohl M, Dittrich K, Ehrich J, et al. Behandlung der Purpura-Schönlein-Henoch-Nephritis bei Kindern und Jugendlichen. Monatsschr Kinderheilkd. 2013;161:543–53. https://doi.org/10.1007/s00112-013-2896-5.

    Article  Google Scholar 

Download references

Acknowledgements

We thank the colleagues and study nurses of the participating centers for collecting the data and supporting this work.

Funding

Open Access funding enabled and organized by Projekt DEAL. Financial support was provided by the German Society of Pediatric Nephrology.

Author information

Authors and Affiliations

  1. Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

    Sarina Butzer, Charlotte Gimpel & Martin Pohl

  2. University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Pediatrics, Cologne, Germany

    Sarina Butzer & Gesa Schalk

  3. Department of Pediatric Kidney, Liver and Metabolic Diseases, Children’s Hospital, Hannover Medical School, Hannover, Germany

    Imke Hennies

  4. Department of Pediatric Nephrology, Charité University Hospital, Berlin, Germany

    Jutta Gellermann

  5. University Children’s Hospital Münster, Münster, Germany

    Sabine König

  6. Department of Pediatrics II, Children’s Hospital, University of Duisburg-Essen, Essen, Germany

    Anja K. Büscher

  7. Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Anja Lemke

Authors
  1. Sarina Butzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Imke Hennies
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charlotte Gimpel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jutta Gellermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gesa Schalk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sabine König
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anja K. Büscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anja Lemke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Martin Pohl
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The study was planned and designed by MP, IH and SB. Data acquisition was accomplished by MP, IH, CG, JG, GS, SK, AKB, and AL. Data analysis was conducted by CG, IH and SB. Interpretation of data was done by MP, IH and SB. The manuscript was written by SB. All authors commented on the manuscript. All authors read and approved the final manuscript. All authors have agreed to be personally accountable for the author's own contributions and ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated, resolved, and the resolution documented in the literature. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Sarina Butzer.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the ethics committee of the Albert Ludwig’s University of Freiburg, Germany. The data used in the study was pseudonymised before its use. Written consent has been obtained from all participants/legal guardians. Access to the data was consented and included in the formal ethics approval.

Consent for publication

Written consent for data analysis for publication has been obtained from all participants/legal guardians.

Competing interests

The authors declare that there is no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Comparative subgroup analysis. Of 66 patients, we identified 28 children with crescentic glomeruli and/or nephrotic syndrome at onset of IgAVN. Referring to the German Society of Pediatric Nephology, a corticosteroid pulse therapy only would have been recommended. Of these 28 children, 17 received corticosteroid pulse therapy per protocol, 11 did not receive any immunosuppressive therapy. We therefore performed a comparative subgroup analysis which showed similar improvements of clinical symptoms and proteinuria.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Butzer, S., Hennies, I., Gimpel, C. et al. Early clinical course of biopsy-proven IgA vasculitis nephritis. BMC Pediatr 22, 570 (2022). https://doi.org/10.1186/s12887-022-03611-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12887-022-03611-9

Keywords

BMC Pediatrics

ISSN: 1471-2431

Contact us